BCL3 and B-cell non-Hodgkin lymphoma: This is consistent with findings of previously studies reporting dysregulation of BCL3 expression in T/B cell leukemia [16–18], Hodgkin lymphoma [19, 20], T/B cell lymphoma [21, 22].